StoryFunding
Linnaeus closes $12M Series B led by Kairos Ventures
Linnaeus announced a $12 million Series B round led by Kairos Ventures, with participation from the Penn Medicine Co-Investment Fund, to advance clinical development.
More on Linnaeus Therapeutics
- ARPA-H awards Linnaeus $22M to test LNS8801 for healthspan preservation in the PROSPR trialFeb 2026
- LNS8801 demonstrates exceptional safety in phase 1/2 cancer trials with 100+ patients treated2025
- Linnaeus closes $4.4M Series A led by Kairos Ventures2018
- Linnaeus Therapeutics founded as University of Pennsylvania spinout2016